About: Clinical characteristics of eosinophilic asthma exacerbations

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Clinical characteristics of eosinophilic asthma exacerbations Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Clinical characteristics of eosinophilic asthma exacerbations
Creator	Sikazwe, Chisha Chidlow, Glenys Smith, David Khoo, Siew-Kim Laing, Ingrid Backer, Vibeke Bjerregaard, Asger Fally, Markus Le Souëf, Peter Porsbjerg, Celeste
Source	Medline; PMC
abstract	BACKGROUND AND OBJECTIVE: Airway eosinophilia is associated with an increased risk of asthma exacerbations; however, the impact on the severity of exacerbations is largely unknown. We describe the sputum inflammatory phenotype during asthma exacerbation and correlate it with severity and treatment response. METHODS: Patients presenting to hospital with an asthma exacerbation were recruited during a 12‐month period and followed up after 4 weeks. Induced sputum was collected at both visits. Patients underwent spirometry, arterial blood gas analysis, fractional exhaled nitric oxide analysis, white blood cell counts and a screening for common respiratory viruses and bacteria. An eosinophilic exacerbation (EE) was defined as having sputum eosinophils ≥ 3% and a non‐eosinophilic exacerbation as < 3% (NEE). RESULTS: A total of 47 patients were enrolled; 37 (79%) had successful sputum induction at baseline, of whom 43% had sputum eosinophils ≥3% (EE). Patients with EE had a significantly lower forced expiratory volume in 1 s (FEV(1)) % predicted (70.8%, P = 0.03) than patients with NEE (83.6%). Furthermore, EE patients were more likely to require supplemental oxygen during admission (63% vs 14%, P = 0.002). The prevalence of respiratory viruses was the same in EE and NEE patients (44% vs 52%, P = 0.60), as was bacterial infection (6% vs 14%, P = 0.44). Fractional expiratory nitric oxide (FeNO) correlated with sputum %‐eosinophils (ρ = 0.57, P < 0.001), and predicted airway eosinophilia with a sensitivity of 86% and a specificity of 70%. CONCLUSION: Our findings suggest that eosinophilic asthma exacerbations may be clinically more severe than NEEs, supporting the identification of these higher risk patients for specific interventions.
has issue date	2016-09-21(xsd:dateTime)
bibo:doi	10.1111/resp.12905
bibo:pmid	27649851
has license	no-cc
sha1sum (hex)	8437cbc2f0e2ce1dd647e1b059d19a177fd5dce2
schema:url	https://doi.org/10.1111/resp.12905
resource representing a document's title	Clinical characteristics of eosinophilic asthma exacerbations
has PubMed Central identifier	PMC7169111
has PubMed identifier	27649851
schema:publication	Respirology
resource representing a document's body	covid:8437cbc2f0e2ce1dd647e1b059d19a177fd5dce2#body_text
is schema:about of	named entity 'arterial blood gas' named entity 'prevalence' named entity 'eosinophilic asthma' named entity 'exhaled nitric oxide' named entity 'risk' named entity 'Patients' named entity 'Results' named entity 'patients' named entity 'sputum' named entity 'describe' named entity 'forced expiratory volume' named entity 'identification' named entity 'successful' named entity 'correlate' named entity 'eosinophilic' named entity 'white blood cell counts' named entity 'nitric oxide' named entity 'eosinophilia' named entity 'eosinophilic asthma' named entity 'sputum' named entity 'Airway' named entity 'viruses' named entity 'asthma exacerbations' named entity 'sputum' named entity 'asthma exacerbation' named entity 'feV' named entity 'Streptococcus pneumoniae' named entity 'FEV' named entity 'eosinophils' named entity 'asthma exacerbation' named entity 'eosinophils' named entity 'sputum' named entity 'inflammatory disease' named entity 'COPD' named entity 'phenotype' named entity 'ppb' named entity 'neutrophils' named entity 'virus' named entity 'mucus' named entity 'sputum' named entity 'acute asthma' named entity 'beta-2 agonists' named entity 'prognostic' named entity 'FEV' named entity 'attenuate' named entity 'FEV' named entity 'asthma' named entity 'eosinophils' named entity 'salbutamol' named entity 'FEV' named entity 'inflammation' named entity 'sputum' named entity 'viral infection' named entity 'phenotype' named entity 'Solna' named entity '12.8' named entity 'respiratory syncytial virus' named entity 'Arterial blood gases' named entity 'FeNO' named entity 'Staphylococcus aureus' named entity 'inflammatory markers' named entity 'FEV' named entity 'eosinophils' named entity 'eosinophilic' named entity 'expectorate' named entity 'inflammatory' named entity 'acute asthma' named entity 'arterial blood gas' named entity 'ROC' named entity 'ppb' named entity 'phenotype' named entity 'eosinophils'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software